GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the New Drug Application (NDA) for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results